HPN 2022 August

Page 26

26

PEER REVIEW: GOUT

Closing the Gap: Improving Pharmacist Knowledge of Gout Management Written by Dr. Emma Dorris (Scientist, UCD), Mariosa Kieran (Pharmacist, Mater Misericordiae University Hospital), Professor Nicola Dalbeth (Consultant Rheumatologist, University of Auckland) and Professor Geraldine McCarthy (Consultant Rheumatologist, Mater Misericordiae University Hospital/UCD) MSU crystals. The goal of urate lowering therapy is to reduce serum urate to a therapeutic target level, thereby permitting MSU crystals to dissolve, in addition to preventing further crystal formation and deposition.

Dr. Emma Dorris (Scientist, UCD)

Professor Geraldine McCarthy (Consultant Rheumatologist, Mater Misericordiae University Hospital/UCD)

Mariosa Kieran (Pharmacist, Mater Misericordiae University Hospital)

Professor Nicola Dalbeth (Consultant Rheumatologist, University of Auckland)

Gout is the most common form of inflammatory arthritis in adults. The incidence of gout is rising. People with gout have an increased risk of cardiovascular disease, and gout is associated with a number of comorbidities including diabetes and renal impairment. The increased incidence of gout together with increased cardiovascular risk and comorbidities is a significant public health challenge.

Unlike other common rheumatic diseases, the underlying cause of gout is well understood. Gout is caused by hyperuricaemia, too much uric acid in the body. This can occur due an underexcretion and/or overproduction of urate, which leads to monosodium urate (MSU) crystal formation and deposition in joints and tissues in susceptible individuals (figure 1). Acute gout flares occur as an inflammatory response to the

AUGUST 2022 • HPN | HOSPITALPROFESSIONALNEWS.IE

An important issue in urate lowering therapy is that paradoxically, initiation of urate lowering therapy can actually induce a gout attack. This happens because the urate lowering therapy causes MSU crystals to be shed from the articular cartilage into the joint space, resulting in acute inflammation. To prevent this, a low dose of anti-inflammatory prophylaxis, such as colchicine, is recommended for at least the first three to six months following initiation of urate lowering therapy. Community pharmacists are the most easily accessible members of a patient’s health care team. Pharmacists are often a key source of information on disease management and patients have confidence in them. Pharmacists act as a critical resource for effective management of disease, particularly when chronic such as gout. Thus, open communication and education between the pharmacy and prescriber communities is essential to provide the most up-to-date and appropriate patient care. However, pharmacists frequently report a lack of patient treatment plan information and clinical connection to other healthcare professionals as barriers to providing optimal care to patients. The use of low dose colchicine as a prophylaxis is an example of this gap in knowledge translation. Colchicine use in gout is most commonly used in the treatment of acute gout flares in a strictly time limited fashion. Legacy prescribing, whereby short or intermediate-term medications are

not appropriately discontinued, is prevalent. Patients, and indeed pharmacists, can be unsure whether the prescribed colchicine is intended as a prophylaxis or is a legacy prescription that was previously prescribed in case of flare. This confusion can be magnified by lack of clear, definitive statements on updated best practices from national bodies and the time lag in incorporating professional body recommendations into readily accessible drug information sources, e.g. the product Summary of Product Characteristics, the British National Formulary. Pharmacists have reported that the advice on use of colchicine as a prophylaxis in their typical reference manuals is poorly defined in comparison to its use for acute flares. This can lead to conflicting advice being given to patients from their pharmacists and rheumatologists about gout management, particularly in relation to colchicine use. This prompted research into the pharmacist knowledge of gout management, leading to the development of an educational intervention for pharmacists. Our research showed that pharmacist-knowledge of gout management in Ireland was not in line with current European (EULAR) gout management guidelines. However, we also demonstrated that pharmacists do not typically use disease management guidelines as standard sources of information. As such, there is a knowledge gap in the most up to date recommendations for gout management. Given the wide number of conditions encountered on a daily basis in community pharmacy, this is somewhat understandable. As such, a dedicated effort must be made by prescribers and professional societies to communicate treatment standards to pharmacists.


Turn static files into dynamic content formats.

Create a flipbook

Articles inside

Nurse Prescribing in A Private Cardiology Outpatient Setting

18min
pages 94-97

Current Treatment Options for Benign Prostatic Hyperplasia

16min
pages 90-93

Benign Prostatic Hyperplasia (BPH)

8min
pages 83-84

Contraceptive Choice in Women on Antiepileptic Drugs (AEDs)

5min
page 81

Deactivation of Implantable Cardioverter Defibrillators in end-of-life situations – more progress needed

12min
pages 74-76

HEPATITIS C: Roadmap to Zero- The Elimination of Hepatitis C by 2030

11min
pages 62, 64-65

Management and Treatment of Addison’s Disease

9min
pages 60-61

Pulmonary Hypertension in COPD

6min
page 59

Eoisinophils as a Treatable Target in COPD

6min
page 58

Management and Treatment of Osteoporosis

12min
pages 54-55

Management and Treatment of Polymyalgia Rheumatica

16min
pages 49-52

The importance of cancer clinical trials as illustrated by HER2+ breast cancer

11min
pages 44, 46-47

Lymphoedema Treatment and Management

4min
page 42

The Unintended Consequences of Centralisation of Colon Cancer Surgery

5min
page 40

Malignant Pleural Effusion: Diagnosis and management

14min
pages 36-39

What is psoriasis?

7min
pages 33-34

Management of Erectile Dysfunction in Ireland

11min
pages 28, 30, 32

Closing the Gap: Improving Pharmacist Knowledge of Gout Management

6min
pages 26-27

Why is Healthcare Still not Safe?

11min
pages 24-25

Advanced Training for Medical Workers

8min
pages 22-23

A Pharmacist Amongst Paramedics

10min
pages 14-15

Clinical R&D

25min
pages 98-100

Peer Review: HER2+ Breast Cancer

20min
pages 44-48

Increasing Specialised Care for Eye Patients

19min
pages 18-23

Peer Review: An Overview of Psoriasis

24min
pages 33-39

Why is Healthcare still not Safe?

49min
pages 24-32

Cardiothoracic Ward opens at University Hospital Galway

8min
pages 16-17

New appointments at Pharmacy Regulator

4min
pages 12-13

Enhancing Cancer Research in Ireland

4min
page 7

amongst Paramedics

10min
pages 14-15

receives Honour

18min
pages 8-11
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.
HPN 2022 August by IPN Communications LTD - Issuu